Literature DB >> 27173977

Further examination of the reducing transition rate in ultra high risk for psychosis samples: The possible role of earlier intervention.

B Nelson1, H P Yuen2, A Lin3, S J Wood4, P D McGorry2, J A Hartmann2, A R Yung5.   

Abstract

BACKGROUND: The rate of transition to psychotic disorder in ultra high risk (UHR) patients has declined in recent cohorts. The reasons for this are unclear, but may include a lead-time bias, earlier intervention, a change in clinical characteristics of cohorts, and treatment changes. AIMS: In this paper we examined the two possibilities related to reduction in duration of symptoms prior to clinic entry, i.e., lead-time bias and earlier intervention.
METHOD: The sample consisted of all UHR research participants seen at the PACE clinic, Melbourne between 1993 and 2006 (N=416), followed for a mean of 7.5years (the 'PACE 400' cohort). Duration of symptoms was analysed by four baseline year time periods. Analysis of transition rate by duration of symptoms was restricted to more homogenous sub-samples (pre-1998 and pre-2001) in order to minimize confounding effects of change in patient characteristics or treatments. These cohorts were divided into those with a short and long duration of symptoms using a cut-point approach.
RESULTS: Duration of symptoms prior to entry did not reduce significantly between 1993 and 2006 (p=0.10). The group with a short duration of symptoms showed lower transition rates and did not catch up in transition rate compared to the long duration of symptoms group. DISCUSSION: These data suggest that, while earlier intervention or lead-time bias do not fully account for the declining transition rate in UHR cohorts, it appears that earlier intervention may have exerted a stronger influence on this decline than length of follow-up period (lead-time bias).
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Early intervention; Prodrome; Psychosis; Ultra high risk

Mesh:

Year:  2016        PMID: 27173977     DOI: 10.1016/j.schres.2016.04.040

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  10 in total

1.  Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients.

Authors:  Barnaby Nelson; G Paul Amminger; Hok Pan Yuen; Nicky Wallis; Melissa J Kerr; Lisa Dixon; Cameron Carter; Rachel Loewy; Tara A Niendam; Martha Shumway; Sarah Morris; Julie Blasioli; Patrick D McGorry
Journal:  Early Interv Psychiatry       Date:  2017-07-18       Impact factor: 2.732

2.  The neurobiology of transition to psychosis: clearing the cache.

Authors:  Lena Palaniyappan; Tushar Das; Kara Dempster
Journal:  J Psychiatry Neurosci       Date:  2017-09       Impact factor: 6.186

3.  Investigation of structural brain correlates of neurological soft signs in individuals at ultra-high risk for psychosis.

Authors:  Ya Wang; Esmee E Braam; Cassandra M J Wannan; Tamsyn E Van Rheenen; Raymond C K Chan; Barnaby Nelson; Patrick D McGorry; Alison R Yung; Ashleigh Lin; Warrick J Brewer; John Koutsogiannis; Stephen J Wood; Dennis Velakoulis; Christos Pantelis; Vanessa L Cropley
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-08-31       Impact factor: 5.270

4.  The Attenuated Psychosis Syndrome and Facial Affect Processing in Adolescents With and Without Autism.

Authors:  Arija Maat; Sebastian Therman; Hanna Swaab; Tim Ziermans
Journal:  Front Psychiatry       Date:  2020-08-03       Impact factor: 4.157

Review 5.  Can We Predict Psychosis Outside the Clinical High-Risk State? A Systematic Review of Non-Psychotic Risk Syndromes for Mental Disorders.

Authors:  Tae Young Lee; Junhee Lee; Minah Kim; Eugenie Choe; Jun Soo Kwon
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

6.  NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical course.

Authors:  B Nelson; G P Amminger; H P Yuen; C Markulev; S Lavoie; M R Schäfer; J A Hartmann; N Mossaheb; M Schlögelhofer; S Smesny; I B Hickie; G Berger; E Y H Chen; L de Haan; D H Nieman; M Nordentoft; A Riecher-Rössler; S Verma; A Thompson; A R Yung; P D McGorry
Journal:  NPJ Schizophr       Date:  2018-06-25

7.  Duration of basic and attenuated-psychotic symptoms in individuals at clinical high risk for psychosis: pattern of symptom onset and effects of duration on functioning and cognition.

Authors:  Lorna Staines; Ruchika Gajwani; Joachim Gross; Andrew I Gumley; Stephen M Lawrie; Matthias Schwannauer; Frauke Schultze-Lutter; Peter J Uhlhaas
Journal:  BMC Psychiatry       Date:  2021-07-07       Impact factor: 3.630

8.  Commentary: Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence).

Authors:  Barnaby Nelson; G Paul Amminger; Andrew Thompson; Stephen J Wood; Alison R Yung; Patrick D McGorry
Journal:  Front Psychiatry       Date:  2020-05-27       Impact factor: 4.157

9.  Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12 months.

Authors:  C Wenneberg; B Y Glenthøj; L B Glenthøj; B Fagerlund; K Krakauer; T D Kristensen; C Hjorthøj; R A E Edden; B V Broberg; K B Bojesen; E Rostrup; M Nordentoft
Journal:  Eur Psychiatry       Date:  2020-08-07       Impact factor: 5.361

10.  Stress reactivity as a putative mechanism linking childhood trauma with clinical outcomes in individuals at ultra-high-risk for psychosis: Findings from the EU-GEI High Risk Study.

Authors:  I Paetzold; I Myin-Germeys; A Schick; B Nelson; E Velthorst; F Schirmbeck; J van Os; C Morgan; J Hartmann; M van der Gaag; L de Haan; L Valmaggia; P McGuire; M Kempton; U Reininghaus
Journal:  Epidemiol Psychiatr Sci       Date:  2021-05-28       Impact factor: 6.892

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.